{"id":"gnrh-analogue-zoladex","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"40-60","effect":"Decreased libido"},{"rate":"40-60","effect":"Erectile dysfunction"},{"rate":"10-20","effect":"Injection site reactions"},{"rate":"10-15","effect":"Gynecomastia"},{"rate":null,"effect":"Bone density loss (with prolonged use)"},{"rate":"20-30","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zoladex (goserelin) binds to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH followed by sustained suppression of these hormones. This results in castration-level testosterone in males and estrogen suppression in females, making it effective for hormone-sensitive cancers and certain gynecological conditions.","oneSentence":"Zoladex is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:16.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic prostate cancer"},{"name":"Locally advanced prostate cancer (in combination with radiotherapy)"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Breast cancer (premenopausal women)"}]},"trialDetails":[{"nctId":"NCT04325828","phase":"PHASE2","title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2020-04-07","conditions":"Salivary Gland Neoplasms","enrollment":31},{"nctId":"NCT06832774","phase":"PHASE2","title":"Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-01","conditions":"Prostate Cancer Metastatic Disease","enrollment":192},{"nctId":"NCT04557059","phase":"PHASE3","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-11-12","conditions":"Prostatic Neoplasms","enrollment":693},{"nctId":"NCT04293393","phase":"PHASE2","title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2020-10-02","conditions":"Early Breast Cancer","enrollment":200},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT07182279","phase":"PHASE1, PHASE2","title":"Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-08-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":29},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":239},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT05700903","phase":"PHASE4","title":"Contributions to Hypertension With Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-09-20","conditions":"Androgen Deprivation Therapy, Prostate Cancer, Hypertension","enrollment":10},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT07389187","phase":"EARLY_PHASE1","title":"Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mCRPC","enrollment":10},{"nctId":"NCT06523530","phase":"PHASE4","title":"Effect of a GnRH Analog on Hepatic Steatosis","status":"RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2024-11-26","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver, Endometriosis","enrollment":62},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT07340619","phase":"PHASE2","title":"Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-18","conditions":"Metastatic (Stage IV) Melanoma","enrollment":51},{"nctId":"NCT07313241","phase":"PHASE2","title":"Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-11-14","conditions":"Prostate Cancer","enrollment":68},{"nctId":"NCT03809000","phase":"PHASE2","title":"A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2019-04-15","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT03511196","phase":"EARLY_PHASE1","title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-17","conditions":"Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer","enrollment":17},{"nctId":"NCT05628363","phase":"NA","title":"Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-18","conditions":"Prostate Cancer, Cancer of the Prostate","enrollment":28},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT05063786","phase":"PHASE3","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2021-09-14","conditions":"Advanced Breast Cancer","enrollment":27},{"nctId":"NCT01492972","phase":"PHASE3","title":"Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"Proton Collaborative Group","startDate":"2012-01","conditions":"Prostate Cancer","enrollment":192},{"nctId":"NCT06455969","phase":"PHASE4","title":"Adaptions and Resiliency to Multi-Stressor OpeRations","status":"RECRUITING","sponsor":"Bradley Nindl","startDate":"2024-07-15","conditions":"Musculoskeletal Injury, Hypogonadism","enrollment":120},{"nctId":"NCT05625087","phase":"PHASE2","title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2023-10-19","conditions":"Breast Cancer Stage IV","enrollment":162},{"nctId":"NCT05694819","phase":"PHASE2","title":"Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2020-04-17","conditions":"Salivary Gland Cancer","enrollment":56},{"nctId":"NCT00567580","phase":"PHASE3","title":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-02","conditions":"Prostate Cancer","enrollment":1792},{"nctId":"NCT06225284","phase":"PHASE2","title":"Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-08-22","conditions":"Triple Negative Breast Cancer, Premenopausal Breast Cancer","enrollment":124},{"nctId":"NCT04992026","phase":"PHASE2","title":"The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2021-01-01","conditions":"Prostatectomy, Oligometastatic Prostate Cancer, Abiraterone","enrollment":130},{"nctId":"NCT03867357","phase":"","title":"Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2018-12-07","conditions":"Metastatic Prostate Cancer, Androgen Deprivation Therapy","enrollment":60},{"nctId":"NCT06575257","phase":"PHASE2","title":"Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-05-01","conditions":"Prostate Cancer","enrollment":80},{"nctId":"NCT05720260","phase":"PHASE2","title":"Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2023-01-17","conditions":"Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer","enrollment":42},{"nctId":"NCT03311555","phase":"PHASE2","title":"A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2018-03-28","conditions":"Prostate Cancer","enrollment":39},{"nctId":"NCT00099086","phase":"PHASE1","title":"Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2007-01-16","conditions":"Prostate Cancer","enrollment":20},{"nctId":"NCT05781217","phase":"PHASE3","title":"Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624","status":"RECRUITING","sponsor":"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic","startDate":"2023-03-14","conditions":"Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence","enrollment":534},{"nctId":"NCT02221999","phase":"PHASE2, PHASE3","title":"Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"RenJi Hospital","startDate":"2013-09","conditions":"Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer","enrollment":250},{"nctId":"NCT00664456","phase":"PHASE3","title":"Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2008-04","conditions":"Prostate Cancer","enrollment":421},{"nctId":"NCT05945407","phase":"NA","title":"Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2016-08-01","conditions":"Endometrial Neoplasms, Endometrial Neoplasm Malignant, Endometrial Neoplasm Malignant Stage I","enrollment":57},{"nctId":"NCT05801705","phase":"","title":"Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":"Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer, Breast Cancer Patients at Intermediate to High Risk","enrollment":700},{"nctId":"NCT02058706","phase":"PHASE2","title":"LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2014-05","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer","enrollment":71},{"nctId":"NCT05800197","phase":"","title":"Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2014-04-15","conditions":"Breast Cancer, Neoadjuvant Endocrine Therapy","enrollment":300},{"nctId":"NCT04356430","phase":"PHASE2","title":"Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2019-04-01","conditions":"Prostate Cancer","enrollment":75},{"nctId":"NCT03279250","phase":"PHASE2","title":"Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":"Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8","enrollment":86},{"nctId":"NCT01989780","phase":"PHASE2","title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Group","startDate":"2014-01","conditions":"Metastatic Breast Cancer","enrollment":160},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT02603679","phase":"PHASE2","title":"Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2015-02","conditions":"Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor","enrollment":181},{"nctId":"NCT00003653","phase":"PHASE3","title":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1999-01-05","conditions":"Prostate Cancer","enrollment":1386},{"nctId":"NCT04736108","phase":"PHASE2","title":"Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2021-05","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT04203212","phase":"","title":"BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH","status":"COMPLETED","sponsor":"424 General Military Hospital","startDate":"2019-10-01","conditions":"Endometriosis, Bone Density, Muscle","enrollment":41},{"nctId":"NCT00004054","phase":"PHASE3","title":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2000-01","conditions":"Prostate Cancer","enrollment":397},{"nctId":"NCT01280045","phase":"NA","title":"Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy","status":"TERMINATED","sponsor":"University of Sao Paulo","startDate":"2011-01","conditions":"UTERINE LEIOMYOMA","enrollment":5},{"nctId":"NCT02592083","phase":"PHASE2","title":"Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Hatschek","startDate":"2015-10","conditions":"Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor","enrollment":10},{"nctId":"NCT00068601","phase":"PHASE3","title":"S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2003-10","conditions":"Breast Cancer, Infertility, Menopausal Symptoms","enrollment":257},{"nctId":"NCT01163084","phase":"PHASE1, PHASE2","title":"Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-09","conditions":"Prostate Adenocarcinoma, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7","enrollment":10},{"nctId":"NCT03054168","phase":"PHASE3","title":"Systemic Hormones and Muscle Protein Synthesis","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2016-12-15","conditions":"Sarcopenia, Muscle Hypotrophy, Muscle Atrophy","enrollment":34},{"nctId":"NCT03137368","phase":"PHASE3","title":"A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2018-08-09","conditions":"CYP2D6 Polymorphism","enrollment":300},{"nctId":"NCT01638247","phase":"PHASE3","title":"Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2012-08","conditions":"Male Breast Cancer","enrollment":56},{"nctId":"NCT03444025","phase":"PHASE2","title":"Neoadjuvant Goserelin for Triple Negative Breast Cancer","status":"UNKNOWN","sponsor":"Kasr El Aini Hospital","startDate":"2018-03","conditions":"Breast Cancer Triple Negative","enrollment":180},{"nctId":"NCT02483767","phase":"PHASE3","title":"Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2015-06","conditions":"Breast Cancer","enrollment":98},{"nctId":"NCT01023061","phase":"PHASE2","title":"Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2010-03","conditions":"Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer","enrollment":24},{"nctId":"NCT00658697","phase":"PHASE2","title":"Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2008-06","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT01750398","phase":"PHASE2","title":"Bipolar Androgen-based Therapy for Prostate Cancer (BAT)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-01","conditions":"Recurrent Prostate Cancer","enrollment":33},{"nctId":"NCT00081159","phase":"PHASE2","title":"Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-07","conditions":"Metastatic Cancer, Prostate Cancer","enrollment":80},{"nctId":"NCT00586898","phase":"PHASE2","title":"Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-07","conditions":"Prostate, Cancer, Hormonal Cycling","enrollment":36},{"nctId":"NCT00454571","phase":"PHASE2","title":"Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06","conditions":"Recurrent Prostate Cancer","enrollment":37},{"nctId":"NCT01088529","phase":"PHASE2","title":"Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer","status":"COMPLETED","sponsor":"Cougar Biotechnology, Inc.","startDate":"2009-12","conditions":"Prostate Cancer","enrollment":66},{"nctId":"NCT00512668","phase":"PHASE1","title":"Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-09","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer","enrollment":24},{"nctId":"NCT00849082","phase":"PHASE3","title":"Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1987-05","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT01581944","phase":"PHASE3","title":"Gonadotropin-releasing Hormone Agonist Prior to Myomectomy","status":"COMPLETED","sponsor":"Mt. Hope Maternity Hospital","startDate":"2008-01","conditions":"Fibroids","enrollment":68},{"nctId":"NCT00654524","phase":"PHASE4","title":"Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2008-03","conditions":"Endometriosis","enrollment":60},{"nctId":"NCT00002881","phase":"PHASE3","title":"Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1996-10","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT00746031","phase":"PHASE4","title":"Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2008-12","conditions":"Fibroid, Leiomyoma","enrollment":30},{"nctId":"NCT00196846","phase":"PHASE2","title":"Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2005-03","conditions":"Breast Cancer","enrollment":62},{"nctId":"NCT00433173","phase":"NA","title":"Insulin Sensitivity in Men With the Metabolic Syndrome","status":"SUSPENDED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2006-05","conditions":"Metabolic Syndrome","enrollment":72},{"nctId":"NCT00948805","phase":"PHASE3","title":"Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2009-01","conditions":"Infertility","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"GnRH analogue (Zoladex)","genericName":"GnRH analogue (Zoladex)","companyName":"University of Edinburgh","companyId":"university-of-edinburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zoladex is a GnRH agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production. Used for Metastatic prostate cancer, Locally advanced prostate cancer (in combination with radiotherapy), Endometriosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}